Avanos Medical Inc AVNS Stock Analysis
- NYSE
- Stock
- Market closed · opens Monday 9:30 AM ET
$24.99 unchanged at close Oct 16
Last close · Previous close $24.99
- Market cap
- At the Oct 16 close
- P/E ratio
- n/mLoss over last 12 months
- Diluted EPS
- −$1.60Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$24.99unchangedFri, Oct 16 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$24.99Oct 15
- Volume0.00Oct 16 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume0.00Last 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $10.64 to $25.49; now $24.99
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Oct 16 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
AVNS beat the S&P 500 in 2 of 7 periods.
| Period | AVNS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | AVNS: unchanged S&P 500: up 1.5% | AVNS trailed the S&P 500 by 1.5 percentage points Trailed |
| 3M | AVNS: up 0.1% S&P 500: up 1.9% | AVNS trailed the S&P 500 by 1.8 percentage points Trailed |
| YTD | AVNS: up 122.5% S&P 500: up 12.8% | AVNS beat the S&P 500 by 109.7 percentage points Beat |
| 1Y | AVNS: up 117.9% S&P 500: up 16.8% | AVNS beat the S&P 500 by 101.1 percentage points Beat |
| Long term | ||
| 3Y | AVNS: up 32.5% S&P 500: up 81.5% +9.8% vs +22.0% a year | AVNS trailed the S&P 500 by 49.0 percentage points Trailed |
| 5Y | AVNS: down 23.9% S&P 500: up 83.1% −5.3% vs +12.9% a year | AVNS trailed the S&P 500 by 107.0 percentage points Trailed |
| 10Y | AVNS: down 26.8% S&P 500: up 319.6% −3.1% vs +15.4% a year | AVNS trailed the S&P 500 by 346.4 percentage points Trailed |
$10,000 invested in AVNS 10 years ago (Oct 14, 2016) would be worth about $7,322 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,964.
AVNS beat the S&P 500 in 2 of 7 periods.
| Period | AVNS and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | AVNS: unchanged S&P 500: up 1.2% | AVNS trailed the S&P 500 by 1.2 percentage points Trailed |
| 3M | AVNS: up 0.1% S&P 500: up 1.7% | AVNS trailed the S&P 500 by 1.6 percentage points Trailed |
| YTD | AVNS: up 122.5% S&P 500: up 11.9% | AVNS beat the S&P 500 by 110.6 percentage points Beat |
| 1Y | AVNS: up 117.9% S&P 500: up 15.5% | AVNS beat the S&P 500 by 102.4 percentage points Beat |
| Long term | ||
| 3Y | AVNS: up 32.5% S&P 500: up 75.0% +9.8% vs +20.5% a year | AVNS trailed the S&P 500 by 42.5 percentage points Trailed |
| 5Y | AVNS: down 23.9% S&P 500: up 71.2% −5.3% vs +11.4% a year | AVNS trailed the S&P 500 by 95.1 percentage points Trailed |
| 10Y | AVNS: down 26.8% S&P 500: up 258.1% −3.1% vs +13.6% a year | AVNS trailed the S&P 500 by 284.9 percentage points Trailed |
$10,000 invested in AVNS 10 years ago (Oct 14, 2016) would be worth about $7,322 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,813.
All-time high
$72.65
Closing high on . Now 65.6% below that record.
Split-adjusted daily closes since Oct 21, 2014.
Stock splits
AVNS hasn’t split since its price history begins in 2014.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q1 FY26, the quarter ended Mar 31, 2026. “Last 12 months” means the four quarters from Apr 1, 2025 to Mar 31, 2026, and balance-sheet figures are as of Mar 31, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $715.90Mup 3.9%
- Net income
- −$74.40M
- Diluted EPS
- −$1.60
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q2 FY24 (Jun 30, 2024) | $171.70M | $1.80M | $0.04 |
| Q3 FY24 (Sep 30, 2024) | $170.40M | $4.30M | $0.09 |
| Q4 FY24 (Dec 31, 2024) | $179.60M | −$397.30M | −$8.64 |
| Q1 FY25 (Mar 31, 2025) | $167.50M | $6.60M | $0.14 |
| Q2 FY25 (Jun 30, 2025) | $175.00M | −$76.80M | −$1.66 |
| Q3 FY25 (Sep 30, 2025) | $177.80M | −$1.40M | −$0.03 |
| Q4 FY25 (Dec 31, 2025) | $180.90M | −$1.30M | −$0.02 |
| Q1 FY26 (Mar 31, 2026) | $182.20M | $5.10M | $0.11 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $587.00M | $6.30M | $0.13 |
| FY22 (Dec 31, 2022) | $684.10M | $50.50M | $1.07 |
| FY23 (Dec 31, 2023) | $673.30M | −$61.80M | −$1.32 |
| FY24 (Dec 31, 2024) | $687.80M | −$392.10M | −$8.53 |
| FY25 (Dec 31, 2025) | $701.20M | −$72.90M | −$1.57 |
Margins
- Gross 50.0%
- Operating −8.3%
- Net −10.4%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $11.50MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$36.70MLast 12 months
- Capital spending$25.20MLast 12 months
- 1.6%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $1.70MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$1.70MLast 12 months
15% of free cash flow
Balance sheet
- $65.60MAs of Mar 31, 2026
Cash plus short- and long-term marketable securities on the Mar 31, 2026 balance sheet.
- Total debt$138.40MAs of Mar 31, 2026
- Net debt$72.80MAs of Mar 31, 2026
- 2.48As of Mar 31, 2026
Current assets divided by current liabilities on the Mar 31, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.18As of Mar 31, 2026
Total debt divided by shareholders’ equity on the Mar 31, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 4 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✗Net income was positive: not passed
- ✓Operating cash flow was positive: passed
- ✓Return on assets improved: passed
- ✓Operating cash flow exceeded net income: passed
- ✗Long-term debt fell relative to assets: not passed
- ✗Current ratio improved: not passed
- ✗Share count didn’t rise: not passed
- ✗Gross margin improved: not passed
- ✓Asset turnover (revenue ÷ assets) improved: passed
- −9.6%Last 12 months
Over the last 12 months, Avanos Medical lost money: its net loss was 9.6% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - −7.0%Last 12 months
Over the last 12 months, Avanos Medical’s net loss was 7.0% of its total assets (averaged over the last four quarter-ends).
ROA = Net income (last 12 months) ÷ Average total assets
About Avanos Medical Inc
Avanos Medical, Inc. is a medical technology company focused on delivering clinically superior medical device solutions that will help patients get back to what matters. Headquartered in Alpharetta, Georgia, we are committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized brands globally and holds leading market positions in multiple categories across its portfolio.
- Sector
- Healthcare
- Industry
- Medical Devices
- Headquarters
- Georgia, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- NYSE
- Asset type
- Common stock
- Price history since
AVNS news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
AVNS stock FAQ
What is AVNS stock’s price today?
Avanos Medical (AVNS) traded at $24.99 at the close on , unchanged from the previous close of $24.99. Over the past 52 weeks it has traded between $10.64 and $25.49.
If you invested $1,000 in AVNS 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in AVNS on would be worth about $732 at the close on , a total return of −26.8%. The same $1,000 would be worth $761 if invested five years ago and $2,179 if invested one year ago. Past performance doesn’t predict future returns.
What is AVNS’s P/E ratio?
AVNS’s P/E ratio isn’t meaningful right now because its earnings over the four quarters to are negative (diluted EPS of −$1.60).
How much revenue does Avanos Medical make?
Avanos Medical reported $715.9 million of revenue over the four quarters to , up 3.9% from the twelve months before. In its latest quarter (Q1 FY26, ended ) revenue was $182.2 million, up 8.8% from a year earlier.
Is Avanos Medical profitable?
Not over the four quarters to . Avanos Medical reported a net loss of $74.4 million across those four quarters on $715.9 million of revenue.
What are AVNS’s earnings per share?
AVNS’s diluted earnings per share were −$1.60 over the four quarters to , compared with −$8.37 in the twelve months before. The latest quarter (Q1 FY26) brought $0.11 per share, against $0.14 a year earlier (how EPS works).
Does AVNS pay a dividend?
Avanos Medical hasn’t paid a dividend in the last twelve months.
What is AVNS’s 52-week high and low?
Over the past 52 weeks AVNS has traded as low as $10.64 and as high as $25.49. At $24.99 at the close on , it is 2.0% below that high and 134.9% above the low.
What is AVNS’s all-time high?
AVNS’s highest closing price was $72.65 on , adjusted for stock splits. At $24.99 at the close on , it is 65.6% below that record.
Has AVNS stock ever split?
No. AVNS hasn’t split since its price history begins in 2014.
How has AVNS stock performed?
Including dividends and measured to the close on , AVNS has returned +122.5% so far this year and +117.9% over the past year, and −23.9% over five years (−5.3% a year). Over the same periods the S&P 500, measured by SPY, returned +12.8%, +16.8% and +83.1%. Past performance doesn’t predict future returns.
What sector and industry is Avanos Medical in?
Avanos Medical is in the Healthcare sector and the Medical Devices industry, and is headquartered in Georgia, USA.
What exchange does AVNS trade on?
Avanos Medical trades on the NYSE under the ticker symbol AVNS. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.